Clinical Trial Update: Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of Polyoxidonium nasal and sublingual spray (6 mg/mL) in children aged 1-12 with acute respiratory infection; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Infection

Drugs mentioned

• Polyoxidonium

Snippet

Sponsor: NPO Petrovax | Conditions: Acute Respiratory Infection | Phase 3 | Status: COMPLETED | Results posted: 2020-06-25